Kemwell Announces Successful FDA Inspection at Bangalore Facility
PTSM: Pharmaceutical Technology Sourcing and Management
The company announced that no Form 483 was observed at the company’s facility in Bangalore, India.
On Feb. 20, 2017, Kemwell Biopharma announced that its oral solids manufacturing facility in Bangalore, India successfully completed an FDA inspection. The inspection confirmed that the site is compliant with principles of current good manufacturing practices and no Form 483 observations were issued. In a statement, the company said the audit was triggered by an abbreviated new drug application filed for a customer. This facility is part of Kemwell’s pharmaceutical business for which Kemwell has signed a purchase agreement with Recipharm.
Source: Kemwell
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
